Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2024-09-05 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is titled "INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST HALF 2024 FINANCIAL RESULTS AND BUSINESS UPDATE". It explicitly states the purpose is to announce a conference call to discuss the first half 2024 financial results. This structure—announcing a call to discuss results—is characteristic of an Earnings Release (ER) or a Call Transcript (CT) announcement. Since the text only announces the call details, participants, and provides links, it is not the transcript itself, nor is it the full financial report (10-K or IR). It is the announcement leading up to the discussion of the results. The closest fit among the provided definitions is 'Earnings Release' (ER), as this announcement precedes the detailed release or call where the results are discussed, or 'Call Transcript' (CT) if the document was the transcript itself. Given the focus on announcing the *call* for the *results*, ER is the most appropriate classification for the announcement itself, although it is very close to an announcement of a call (which might sometimes fall under RNS). However, since it pertains directly to the financial results period, ER is preferred over the general RNS fallback. The document length is moderate (5062 chars), but the content is purely an announcement of an event to discuss results. H1 2024
2024-09-05 English
6-K
Foreign Filer Report
2024-09-04 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing the company's participation in an upcoming investor conference (H.C. Wainwright 26th Annual Global Investment Conference). It provides details about the event, a brief company overview, and standard disclaimers. This type of announcement, which informs investors about management's schedule for engaging with the investment community, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or often falls under general investor relations communication. Since it is an announcement about participation in an investor conference, it is most closely aligned with Investor Presentation (IP) materials or general investor communication. However, given the specific definitions, it is not a formal report (10-K, IR, ER, MDA) nor a specific transaction notice (DIV, SHA, POS). It is an announcement intended for investors regarding future engagement. In many databases, such announcements are categorized under Investor Presentation (IP) or sometimes Regulatory Filings (RNS) if no better fit exists. Since it is a direct communication about investor engagement and strategy presentation opportunities, IP is the most appropriate fit among the specific options, although it is an announcement *about* participation rather than the presentation itself. Given the options, and recognizing this is a standard investor relations update, IP is selected as the best fit for investor-focused material.
2024-09-04 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated September 4, 2024, announcing that an executive from Innate Pharma will participate in the 'H.C. Wainwright 26th Annual Global Investment Conference' on September 10, 2024. This is an announcement about the company's participation in an investor-facing event, which is a common activity for investor relations. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal proxy/AGM material. The closest fit among the provided categories for an announcement regarding participation in a major investment conference, which is designed to present company strategy and financials to investors, is 'Investor Presentation' (IP) or potentially a general 'Regulatory Filing' (RNS) if no better fit exists. However, since the core purpose is to inform investors about an upcoming presentation/meeting opportunity, 'Investor Presentation' (IP) is the most contextually relevant classification, even though it's an announcement *about* participation rather than the presentation itself. Given the options, and recognizing this is a standard IR communication about engaging with investors at a conference, IP is selected over the generic RNS.
2024-09-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated August 1st, 2024, announcing the company's participation in an upcoming investor conference (BTIG Virtual Biotechnology Conference on August 5-6, 2024). This type of announcement, which informs investors about management's schedule for non-earnings related investor events (like conferences or roadshows), does not fit neatly into the specific categories like ER (Earnings Release), IP (Investor Presentation), or CT (Call Transcript). It is a general corporate communication regarding investor relations activities. Since it is a specific announcement that doesn't match the primary categories, the most appropriate fallback is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements not covered elsewhere.
2024-08-01 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release from Innate Pharma announcing the participation of its management team in an upcoming investor conference (BTIG Virtual Biotechnology Conference). This type of announcement, which details management's schedule for meeting with investors, is characteristic of materials intended for the investment community to provide updates on strategy and pipeline. While it is an announcement, it is not announcing the release of a formal financial report (like 10-K or IR), nor is it a general regulatory filing (RNS). It specifically relates to investor engagement and presentation opportunities. The closest fit among the provided definitions is 'Investor Presentation' (IP), as these announcements often precede or accompany such engagement, or 'Report Publication Announcement' (RPA) if it were announcing a report, but here it announces conference participation. Given the content focuses on management meeting investors at a specific conference, it aligns best with the spirit of Investor Presentation (IP) materials, which are used to communicate company status to investors, even if this specific document is just the announcement of attendance. However, since the document is purely an announcement about *attending* a conference, and not the presentation itself, and it is not a formal regulatory filing, the most appropriate category for an announcement detailing management's schedule for investor meetings is often grouped with Investor Presentations or sometimes treated as a general Regulatory Filing (RNS) if no better fit exists. Given the options, 'Investor Presentation' (IP) is the most contextually relevant category for an announcement detailing management's schedule for investor conferences, as it serves the same purpose of communicating with investors about company activities.
2024-08-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.